Aardvark Therapeutics, Inc.(AARD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AARD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Aardvark Therapeutics, Inc. (AARD), a Healthcare sector company. AARD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of AARD by reported 13-F value include Decheng Capital, CITADEL ADVISORS, Laurion Capital Management, based on the most recent SEC filings. AARD trades on the Nasdaq exchange and files with the SEC under CIK 1774857. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AARD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aardvark Therapeutics, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-14.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-179.7% YoYOperating Income
-175.3% YoYEPS (Diluted)
+43.1% YoYTotal Assets
+51.2% YoYOp. Cash Flow
-199.5% YoYFree Cash Flow
-198.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $0.00 | — | — |
| Net Income | $-57.6M -179.7% | $-20.6M | — |
| Operating Income | $-62.7M -175.3% | $-22.8M | — |
| EPS (Diluted) | $-2.93 +43.1% | $-5.15 | — |
| Total Assets | $117.2M +51.2% | $77.5M | — |
| Operating Cash Flow | $-54.2M -199.5% | $-18.1M | — |
| Free Cash Flow | $-54.3M -198.2% | $-18.2M | — |
Get alerted when AARD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aardvark Therapeutics, Inc. including:
Top Institutional Holders of AARD
Decheng Capital LLC
$22.6M3,917,299 shCITADEL ADVISORS LLC
$7.4M1,283,166 shLaurion Capital Management LP
$6.0M1,034,459 shVANGUARD CAPITAL MANAGEMENT LLC
$3.2M562,877 shAQR CAPITAL MANAGEMENT LLC
$2.8M480,249 shEcoR1 Capital, LLC
$2.3M396,194 shADAGE CAPITAL PARTNERS GP, L.L.C.
$1.7M300,000 shBlackRock, Inc.
$1.1M187,045 shGEODE CAPITAL MANAGEMENT, LLC
$863.5K149,844 shCANTOR FITZGERALD, L. P.
$671.5K116,582 sh
| Fund | Value | Shares |
|---|---|---|
| Decheng Capital LLC | $22.6M | 3,917,299 |
| CITADEL ADVISORS LLC | $7.4M | 1,283,166 |
| Laurion Capital Management LP | $6.0M | 1,034,459 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.2M | 562,877 |
| AQR CAPITAL MANAGEMENT LLC | $2.8M | 480,249 |
| EcoR1 Capital, LLC | $2.3M | 396,194 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1.7M | 300,000 |
| BlackRock, Inc. | $1.1M | 187,045 |
| GEODE CAPITAL MANAGEMENT, LLC | $863.5K | 149,844 |
| CANTOR FITZGERALD, L. P. | $671.5K | 116,582 |
More Healthcare Companies
View all Healthcare →Put AARD on your watchlist
Track score changes the day Aardvark Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AARD a good stock to buy?
13F Pro's AI-powered analysis of Aardvark Therapeutics, Inc. (AARD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AARD are available on the AARD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AARD is classified as a small company.
Which hedge funds own AARD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AARD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aardvark Therapeutics, Inc.'s investment landscape.